Johnson & Johnson - 63 Year Stock Split History | JNJ

Stock split history for Johnson & Johnson since 1962. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Johnson & Johnson Annual Stock Splits
Johnson & Johnson Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $366.637B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $749.886B 57.50
AbbVie (ABBV) United States $327.632B 18.06
Roche Holding AG (RHHBY) Switzerland $255.245B 0.00
Novartis AG (NVS) Switzerland $245.907B 14.04
Merck (MRK) United States $196.564B 10.05
Pfizer (PFE) United States $136.449B 7.48
Sanofi (SNY) France $118.258B 11.65
Bayer (BAYRY) Germany $30.298B 6.17
Innoviva (INVA) United States $1.346B 14.10
Novo Nordisk (NVO) Denmark $0.000B 21.99